|
1
|
Gurney JG, Davis S, Severson RK, Fang JY,
Ross JA and Robison L: Trends in cancer incidence among children in
the US. Cancer. 78:532–541. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nakagawara A, Li Y, Izumi H, Muramori K,
Inada H and Nishi M: Neuroblastoma. Jpn J Clin Oncol. 48:214–241.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maris J, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park JR, Kreissman SG, London WB, Naranjo
A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka
JM, et al: Effect of tandem autologous stem cell transplant vs
single transplant on event-free survival in patients with high-risk
neuroblastoma: A randomized clinical trial. JAMA. 322:746–755.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park JA and Cheung NKV: Targets and
antibody formats for immunotherapy of neuroblastoma. J Clin Oncol.
38:1836–1848. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zafar A, Wang W, Liu G, Wang X, Xian W,
McKeon F, Foster J, Zhou J and Zhang R: Molecular targeting
therapies for neuroblastoma: Progress and challenges. Med Res Rev.
41:961–1021. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cohn SL, Pearson AD, London WB, Monclair
T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et
al: The international neuroblastoma risk group (INRG)
classification system: An INRG task force report. J Clin Oncol.
27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sokol E, Desai AV, Applebaum MA,
Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin
MS, Hogarty M, Naranjo A, et al: Age, diagnostic category, tumor
grade, and mitosis-karyorrhexis index are independently prognostic
in neuroblastoma: An INRG project. J Clin Oncol. 38:1906–1918.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asgharzadeh S, Pique-Regi R, Sposto R,
Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A and
Seeger RC: Prognostic significance of gene expression profiles of
metastatic neuroblastomas lacking MYCN gene amplification. J Natl
Cancer Inst. 98:1193–1203. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi Y, Yuan J, Rraklli V, Maxymovitz E,
Cipullo M, Liu M, Li S, Westerlund I, Bedoya-Reina OC, Bullova P,
et al: Aberrant splicing in neuroblastoma generates RNA-fusion
transcripts and provides vulnerability to spliceosome inhibitors.
Nucleic Acids Res. 49:2509–2521. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hiwatari M, Seki M, Matsuno R, Yoshida K,
Nagasawa T, Sato-Otsubo A, Yamamoto S, Kato M, Watanabe K,
Sekiguchi M, et al: Novel TENM3-ALK fusion is an alternate
mechanism for ALK activation in neuroblastoma. Oncogene.
41:2789–2797. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fetahu IS and Taschner-Mandl S:
Neuroblastoma and the epigenome. Cancer Metastasis Rev. 40:173–189.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brodeur GM, Seeger RC, Schwab M, Varmus HE
and Bishop JM: Amplification of N-myc in untreated human
neuroblastomas correlates with advanced disease stage. Science.
224:1121–1124. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bresler SC, Weiser DA, Huwe PJ, Park JH,
Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady
PW, et al: ALK mutations confer differential oncogenic activation
and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer
Cell. 26:682–694. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bellini A, Pötschger U, Bernard V,
Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M,
Betts DR, et al: Frequency and prognostic impact of ALK
amplifications and mutations in the European neuroblastoma study
group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1). J Clin
Oncol. 39:3377–3390. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spitz R, Hero B, Ernestus K and Berthold
F: Deletions in chromosome arms 3p and 11q are new prognostic
markers in localized and 4s neuroblastoma. Clin Cancer Res.
9:52–58. 2003.PubMed/NCBI
|
|
17
|
Schleiermacher G, Mosseri V, London WB,
Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A,
Speleman F, et al: Segmental chromosomal alterations have
prognostic impact in neuroblastoma: A report from the INRG project.
Br J Cancer. 107:1418–1422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fong C, White PS, Peterson K, Sapienza C,
Cavenee WK, Kern SE, Vogelstein B, Cantor AB, Look AT and Brodeur
GM: Loss of heterozygosity for chromosomes 1 or 14 defines subsets
of advanced neuroblastomas. Cancer Res. 52:1780–1785.
1992.PubMed/NCBI
|
|
19
|
Brady SW, Liu Y, Ma X, Gout AM, Hagiwara
K, Zhou X, Wang J, Macias M, Chen X, Easton J, et al:
Pan-neuroblastoma analysis reveals age-and signature-associated
driver alterations. Nat Commun. 11:51832020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Janoueix-Lerosey I, Schleiermacher G,
Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier
J, Peuchmaur M, Valent A, et al: Overall genomic pattern is a
predictor of outcome in neuroblastoma. J Clin Oncol. 27:1026–1033.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park JR, Eggert A and Caron H:
Neuroblastoma: Biology, prognosis, and treatment. Pediatr Clin N
Am. 55:97–120. 2008. View Article : Google Scholar
|
|
22
|
Olivera GG, Yáñez Y, Gargallo P, Sendra L,
Aliño SF, Segura V, Sanz MÁ, Cañete A, Castel V, Mora JF, et al:
MTHFR and VDR polymorphisms improve the prognostic
value of MYCN status on overall survival in neuroblastoma
patients. Int J Mol Sci. 21:27142020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Caudle KE, Thorn CF, Klein TE, Swen JJ,
McLeod HL, Diasio RB and Schwab M: Clinical pharmacogenetics
implementation consortium guidelines for dihydropyrimidine
dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol
Ther. 94:640–645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amstutz U, Henricks LM, Offer SM,
Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle
KE, Diasio RB and Schwab M: Clinical Pharmacogenetics
implementation consortium (CPIC) guideline for dihydropyrimidine
dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.
Clin Pharmacol Ther. 103:210–216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Swen JJ, Nijenhuis M, de Boer A, Grandia
L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH,
Schalekamp T, Touw DJ, et al: Pharmacogenetics: From bench to
byte-an update of guidelines. Clin Pharmacol Ther. 89:662–673.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lunenburg CATC, van der Wouden CH,
Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk
AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, et al: Dutch
pharmacogenetics working group (DPWG) guideline for the gene-drug
interaction of DPYD and fluoropyrimidines. Eur J Hum Genet.
28:508–517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pu X, Hildebrandt MAT, Lu C, Lin J,
Stewart DJ, Ye Y, Gu J, Spitz MR and Wu X: PI3K/PTEN/AKT/mTOR
pathway genetic variation predicts toxicity and distant progression
in lung cancer patients receiving platinum-based chemotherapy. Lung
Cancer. 71:82–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jabeen S, Holmboe L, Alnæs GIG, Andersen
AM, Hall KS and Kristensen VN: Impact of genetic variants of RFC1,
DHFR and MTHFR in osteosarcoma patients treated with high-dose
methotrexate. Pharmacogenomics J. 15:385–390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sugishita M, Imai T, Kikumori T, Mitsuma
A, Shimokata T, Shibata T, Morita S, Inada-Inoue M, Sawaki M,
Hasegawa Y and Ando Y: Pharmacogenetic association between GSTP1
genetic polymorphism and febrile neutropenia in Japanese patients
with early breast cancer. Breast Cancer. 23:195–201. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bosó V, Herrero MJ, Santaballa A, Palomar
L, Megias JE, de la Cueva H, Rojas L, Marqués MR, Poveda JL,
Montalar J and Aliño SF: SNPs and taxane toxicity in breast cancer
patients. Pharmacogenomics. 15:1845–1858. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Verscheijden LFM, Koenderink JB, Johnson
TN, de Wildt SN and Russel FGM: Physiologically-based
pharmacokinetic models for children: Starting to reach maturation?
Pharmacol Ther. 211:1075412020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Min S: Design of formulations for
pediatric drugs. Prog Pharm Sci. 43:655–666. 2019.
|
|
33
|
Fernandez E, Perez R, Hernandez A, Tejada
P, Arteta M and Ramos JT: Factors and mechanisms for
pharmacokinetic differences between pediatric population and
adults. Pharmaceutics. 3:53–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ognibene M, De Marco P, Amoroso L, Fragola
M, Zara F, Parodi S and Pezzolo A: Neuroblastoma patients' outcome
and chromosomal instability. Int J Mol Sci. 24:155142023.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Körber V, Stainczyk SA, Kurilov R, Henrich
KO, Hero B, Brors B, Westermann F and Höfer T: Neuroblastoma arises
in early fetal development and its evolutionary duration predicts
outcome. Nat Genet. 55:619–630. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olivera GG, Urtasun A, Sendra L, Aliño SF,
Yáñez Y, Segura V, Gargallo P, Berlanga P, Castel V, Cañete A and
Herrero MJ: Pharmacogenetics in neuroblastoma: What can already be
clinically implemented and what is coming next? Int J Mol Sci.
22:98152021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Urtasun A, Olivera GG, Sendra L, Aliño SF,
Berlanga P, Gargallo P, Hervás D, Balaguer J, Juan-Ribelles A,
Andrés MDM, et al: Personalized medicine in infant population with
cancer: Pharmacogenetic pilot study of polymorphisms related to
toxicity and response to chemotherapy. Cancers (Basel).
15:14242023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Paolini L, Hussain S and Galardy PJ:
Chromosome instability in neuroblastoma: A pathway to aggressive
disease. Front Oncol. 12:9889722022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pediatric Oncology Committee, Chinese
Anti-Cancer Association, Oncology Group, Chinese Association of
Pediatric Surgeons, . Expert consensus on diagnosing and treating
of neuroblastoma in children. Chin J Pediatr Surg. 36:3–7.
2015.
|
|
40
|
Department of Health and Human Services, .
Common Terminology Criteria for Adverse Events (CTCAE). Version
5.0. 2017.
|
|
41
|
Gunderson KL, Steemers FJ, Lee G, Mendoza
LG and Chee MS: A genome-wide scalable SNP genotyping assay using
microarray technology. Nat Genet. 37:549–554. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Conlin LK, Thiel BD, Bonnemann CG, Medne
L, Ernst LM, Zackai EH, Deardorff MA, Krantz ID, Hakonarson H and
Spinner NB: Mechanisms of mosaicism, chimerism and uniparental
disomy identified by single nucleotide polymorphism array analysis.
Hum Mol Genet. 19:1263–1275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Attiyeh EF, London WB, Mossé YP, Wang Q,
Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, et
al: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N
Engl J Med. 353:2243–2253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ambros PF, Ambros IM, Brodeur GM, Haber M,
Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London
WB, et al: International consensus for neuroblastoma molecular
diagnostics: Report from the international neuroblastoma risk group
(INRG) biology committee. Br J Cancer. 100:1471–1482. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thompson D, Vo KT, London WB, Fischer M,
Ambros PF, Nakagawara A, Brodeur GM, Matthay KK and DuBois SG:
Identification of patient subgroups with markedly disparate rates
of MYCN amplification in neuroblastoma: A report from the
international neuroblastoma risk group project. Cancer.
122:935–945. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sansregret L and Swanton C: The role of
aneuploidy in cancer evolution. Cold Spring Harb Perspect Med.
7:a0283732017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bourdeaut F, Ribeiro A, Paris R, Pierron
G, Couturier J, Peuchmaur M and Delattre O: In neuroblastic
tumours, Schwann cells do not harbour the genetic alterations of
neuroblasts but may nevertheless share the same clonal origin.
Oncogene. 27:3066–3071. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Toraman AD, Keser I, Lüleci G, Tunali N
and Gelen T: Comparative genomic hybridization in
ganglioneuroblastomas. Cancer Genet Cytogen. 132:36–40. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Abdel-Hafiz HA, Schafer JM, Chen X, Xiao
T, Gauntner TD, Li Z and Theodorescu D: Y chromosome loss in cancer
drives growth by evasion of adaptive immunity. Nature. 619:624–631.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Müller P, Camacho OV, Yazbeck AM, Wölwer
C, Zhai W, Schumacher J, Heider D, Buettner R, Quaas A and Hillmer
AM: Why loss of Y? A pan-cancer genome analysis of tumors with loss
of Y chromosome. Comput Struct Biotechnol J. 21:1573–1583. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ognibene M, De Marco P, Parodi S, Meli M,
Di Cataldo A, Zara F and Pezzolo A: Genomic analysis made it
possible to identify gene-driver alterations covering the time
window between diagnosis of neuroblastoma 4s and the progression to
stage 4. Int J Mol Sci. 23:65132022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Janssen A, Van Der Burg M, Szuhai K, Kops
GJ and Medema RH: Chromosome segregation errors as a cause of DNA
damage and structural chromosome aberrations. Science.
333:1895–1898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu Y, Yu H, Tang H, Su Y, Shi TL, Liu S,
Xia Q and Xu DJ: PXR polymorphisms have impact on the clinical
efficacy of clopidogrel in patients undergoing percutaneous
coronary intervention. Gene. 653:22–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Richardson M, Kirkham J, Dwan K, Sloan DJ,
Davies G and Jorgensen AL: Association of variants within the GST
and other genes with anti-tubercular agents related toxicity: A
systematic review and meta-analysis. BioRxiv. 9:5158172019.
|
|
55
|
Saito R, Suzuki H, Yamada T, Endo S,
Moriwaki T, Ueno T, Hirose M, Hirai S, Yamato K, Mizokami Y and
Hyodo I: Predicting skin toxicity according to EGFR polymorphisms
in patients with colorectal cancer receiving antibody against EGFR.
Anticancer Res. 33:4995–4998. 2013.PubMed/NCBI
|
|
56
|
Zhuang W, Qiu H, Wang X, Xin S, Huang M
and Zhou Z: Impact of pharmacogenomics on imatinib toxicity in
gastrointestinal stromal tumors. J Clin Oncol. 35:110432017.
View Article : Google Scholar
|
|
57
|
Wei F, Xi C and Shaoxing G: Relationship
between MAPK1 gene polymorphism and gefitinib hepatotoxicity in
NSCLC patients with activating EGFR mutations. Acta Pharm
Sin. 53:760–764. 2018.
|
|
58
|
Jansen RS, Mahakena S, de Haas M, Borst P
and van de Wetering K: ATP-binding cassette subfamily C member 5
(ABCC5) functions as an efflux transporter of glutamate conjugates
and analogs. J Biol Chem. 290:30429–30440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen J, Wang Z, Gao S, Wu K, Bai F, Zhang
Q, Wang H, Ye Q, Xu F, Sun H, et al: Human drug efflux transporter
ABCC5 confers acquired resistance to pemetrexed in breast cancer.
Cancer Cell Int. 21:1–10. 2021.PubMed/NCBI
|
|
60
|
Belkahla S, Khan AUH, Gitenay D, Alexia C,
Gondeau C, Vo DN, Orecchioni S, Talarico G, Bertolini F, Cartron G,
et al: Changes in metabolism affect expression of ABC transporters
through ERK5 and depending on p53 status. Oncotarget. 9:1114–1129.
2018. View Article : Google Scholar : PubMed/NCBI
|
